InsiderClue
← All stocks

Bicara Therapeutics Inc.

BCAX Scheduled selling only
CIK 0002023658 #2204 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$400.72K
$0.00 on a plan · $400.72K straight out of an exercise
Sold at will
$0.00
0 of 2 sales
Net
−$400.72K
$0.00 against sales at will

By person

7 insiders · 2 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Cohlhepp Ryan
President, COO & Interim CEO
—
$400.72K (2) scheduled
−$400.72K
181,641
0.2745%
$4.26M
−17.9%
RA CAPITAL MANAGEMENT, L.P. entity
Director
—
—
—
4,603,418
6.96%
$107.88M
+7.0%
Flynn James E
10% owner
—
—
—
897,587
1.36%
$21.03M
—
Mazumdar Claire
Chief Executive Officer
—
—
—
362,152
0.5473%
$8.49M
+16.9%
Hyep Ivan
Chief Financial Officer
—
—
—
129,855
0.1962%
$3.04M
−10.7%
Raben David
Chief Medical Officer
—
—
—
55,286
0.0835%
$1.30M
+55.7%
Meisner Lara
Chief Legal Officer
—
—
—
0
0.0000%
$0.00
—

Individual transactions

2
Insider
Date
Role
Action
Shares
Price
Amount
Cohlhepp Ryan
8 Sep 2026
President, COO & Interim CEO
Sold after exercise
3,442
$23.43
$80.66K
Cohlhepp Ryan
8 Sep 2026
President, COO & Interim CEO
Sold after exercise
14,058
$22.77
$320.05K
Show all 2 transactions →

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 2
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 17,500
History held since 16 Sep 2024